Mod­er­na CEO Ban­cel of­fers a thumbs-up on lat­est up­date for their CMV pro­gram — with block­buster hopes for what's ahead

Mod­er­na is rolling out a pos­i­tive up­date to their proof-of-con­cept study for their mR­NA pro­gram for a CMV vac­cine — and CEO Stéphane Ban­cel is hap­py to dis­cuss what he sees as a po­ten­tial com­pa­ny-build­ing block­buster in the mak­ing.

Fol­low­ing a third vac­ci­na­tion re­searchers tracked an in­creas­ing lev­el of neu­tral­iz­ing an­ti­body titers, which is ex­act­ly what they want­ed to see.

They $MR­NA re­port:

Neu­tral­iz­ing an­ti­body titers against ep­ithe­lial cell in­fec­tion were greater than 10-fold high­er than CMV-seropos­i­tive base­line titers at the 90 and 180 μg dose lev­els af­ter the third vac­cine, com­pared to 3-fold to 5-fold high­er af­ter the sec­ond vac­ci­na­tion.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER